A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer. Value Health 2017; 20(4): 567-576.Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, et al. A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK ...
BRCA2:I2 = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs withinBRCA2. The pooled RRs were 2.08 (95% CI 1.38–3.12) for Ashkenazi J...
triple-negative breast cancer (TNBC;BRCA1), oestrogen receptor (ER)-positive breast cancer (BC), and human epidermal growth factor receptor 2 (HER2)-negative BC (BRCA2); however, all BC subtypes can occur in association with g
triple-negative breast cancer (TNBC;BRCA1), oestrogen receptor (ER)-positive breast cancer (BC), and human epidermal growth factor receptor 2 (HER2)-negative BC (BRCA2); however, all BC subtypes can occur in association with g
Currently, in most countries clinicalBRCA1/2testing is offered after genetic counseling by clinical cancer geneticist (oncogeneticist) when mutation finding probability exceeds 10%, or even 20% (as in the UK) [18]. Various selection criteria, based on family history, age at onset and tumors cl...
BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) encode for tumor suppressor proteins which are critical regulators of the Homologous Recombination (HR) pathway, the most precise and important DNA damage response mechanism. Dysfunctional HR
Testing for BRCA1 and BRCA2 should focus solely on unambiguously loss-of-function mutations with definitive effect on cancer risk. With modern genomics tools, it is possible to identify all variants in any gene. The challenge is not identification, but interpretation, of making sense of what is...
A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer. Value Health 2017; 20(4): 567-576.Eccleston A, ... Strydom,Ann,Bentley,... 被引量: 0发表: 2017年 The Cost Effectiveness of Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Suscep...
Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing Two cancer susceptibility genes, BRCA1 on chromosome 17q12-21 and BRCA2 on chromosome 13q12-13, are thought to be responsible for similar to 80% of familie... SA Gayther,BAJ Ponder - 《Molecular Medicine ...
BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) encode for tumor suppressor proteins which are critical regulators of the Homologous Recombination (HR) pathway, the most precise and important DNA damage response mechanism. Dysfunctional HR